For healthcare professionals only
GPnotebook

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Prescribing information for Great Britain, Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Webinar resources

Dr Sarah Jarvis, General Practitioner and Medical Broadcaster, London

Chair of the T2 Discussions webinar series alongside several experts

Chronic kidney disease in adult type 2 diabetes: Practical advice for screening, management and referral

Dr Sarah Jarvis and Dr Janaka Karalliedde

  • VIDEO
  • 41 min

Click here to view video

 Chronic kidney disease in adult type 2 diabetes: Practical advice for screening, management and referral

  • Define the importance and impact of chronic kidney disease in adults with type 2 diabetes and its association with cardiovascular disease
  • Examine best practice for managing chronic kidney disease in adults with type 2 diabetes including screening, coding, referrals, managing complications and treatment options
  • VIDEO (SHORT)
  • 10 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • Patient leaflet

Click here to download

Addressing inequalities and socioeconomic factors in adult type 2 diabetes: Strategies to improve treatment outcomes

Dr Sarah Jarvis and Professor Wasim Hanif

  • VIDEO
  • 42 min

Click here to view video

Addressing inequalities and socioeconomic factors in adult type 2 diabetes: Strategies to improve treatment outcomes

  • Understand the inequalities and socioeconomic factors impacting adults with type 2 diabetes
  • Discuss how to address these factors to improve outcomes in adult type 2 diabetes
  • VIDEO (SHORT)
  • 11 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • Downloadable document

Click here to download

How to identify and support Diabetes Distress in adults with type 2 diabetes, and why it matters

Dr Sarah Jarvis & Professor Richard Holt

  • VIDEO
  • 39 min

Click here to view video

How to identify and support Diabetes Distress in adults with type 2 diabetes, and why it matters

  • Understand the definition, characteristic symptoms and impact of diabetes distress in adults with type 2 diabetes
  • Examine best practice for detecting and measuring diabetes distress
  • Discuss strategies to help support your patients with diabetes distress
  • VIDEO (SHORT)
  • 5 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • Downloadable document

Click here to download

  • Leaving soon

How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?

Dr Sarah Jarvis & Dr Kevin Fernando

  • VIDEO
  • 35 min

Click here to view video

How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?

  • Best practice for achieving treatment targets in adults with type 2 diabetes, including how frequently treatment targets should be assessed and key findings from the National Diabetes Audit
  • Practical tips for addressing clinical inertia with our patients
  • The importance of individualising treatment targets and the implications this may have for choice of pharmacotherapy
  • VIDEO (SHORT)
  • 15 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • Downloadable document

Click here to download

Elderly and frail people with type 2 diabetes

Dr Sarah Jarvis

  • VIDEO (Short)
  • 17 min

Click here to view video

Management of type 2 diabetes in the elderly and frail

  • The ideal glycaemic targets for the elderly and frail population with type 2 diabetes
  • How to simplify the management of type 2 diabetes in the elderly and frail population
  • The practicalities of treatment with DPP-4 (dipeptidyl peptidase-4) inhibitors, in particular linagliptin
  • Webinar

Sarah Jarvis
Webinar Series Chair

Watch the most recent webinar

VIEW HERE
  • VIRTUAL WEBINARS
Initiated and funded by
Boehringer Ingelheim
PC-GB-110175 V2 | December 2024

Prescribing information for Great Britain, Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].
PC-GB-110809 | December 2024
PC-GB-109919 V5 | December 2024

This website is for healthcare professionals in the United Kingdom and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in the United Kingdom or the Republic of Ireland by clicking below.

I am
I am not
Trajenta® (linagliptin) prescribing information: GB, NI, ROI.

JARDIANCE® (empagliflozin) prescribing information: GB, NI, ROI.

Prescribing information for the United Kingdom and the Republic of Ireland 

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel